Specialty Chemicals

Bon Natural Life

Bon Natural Life released FY2025 Q2 earnings on September 29 Post-Market (EST), actual revenue USD 3.975 M, actual EPS USD 0.25

Bon Natural Life released FY2025 Semi-Annual Earnings on September 29, 2025 (EST) with actual revenue of USD 7.95 M and EPS of USD 0.5

Bon Natural Life released FY2025 Q1 earnings on September 29 (EST) with actual revenue of USD 3.975 M and EPS of USD 0.25

Tianmei Biotech Signs $16 Million Distribution Deal with Huahai Keyuan

Tianmei Bio Enters into a $18 Million Distribution Agreement with Tianjin Meirui Youli

Tianmei Bio Launches Postbiotic Glycemic Ingredients and Signs Exclusive Agreement with Beijing Huahai

Bon Natural Life released FY2024 Q4 earnings on January 28, 2025 (EST), with actual revenue of 0 USD and EPS of 0 USD

Bon Natural Life released FY2024 9 Months Earnings on January 28, 2025 (EST), with actual revenue of USD 10.18 M and actual EPS of USD -0.2045

Bon Natural Life released FY2024 Annual Earnings on January 28, 2025 (EST), actual revenue USD 23.84 M (forecast USD 42.98 M), actual EPS USD 4.1687 (forecast USD 145)

Bon Natural Life released FY2024 Q3 earnings on January 28 (EST) with actual revenue of 0 USD and EPS of 0 USD

Bon Natural Life released FY2024 Q2 earnings on September 27 (EST), actual revenue USD 5.092 M, actual EPS USD -0.1022

Bon Natural Life released FY2024 Q1 earnings on September 27, 2024 (EST), with actual revenue of USD 5.092 M and EPS of USD -0.1022

Bon Natural Life released FY2024 Semi-Annual Earnings on September 27 (EST), actual revenue USD 10.18 M (forecast USD 18.25 M), actual EPS USD -0.2045 (forecast USD 62.5)

Bon Natural Life released FY2023 9 Months Earnings on February 9, 2024 (EST) with actual revenue of USD 14.15 M and EPS of USD 59.0182

Bon Natural Life released FY2023 Q4 earnings on February 9, 2024 (EST) with actual revenue of 0 USD and EPS of 0 USD

Bon Natural Life released FY2023 annual earnings on February 9, 2024 (EST), actual revenue USD 29.52 M (forecast USD 34.03 M), actual EPS USD 125 (forecast USD 140)

Bon Natural Life released FY2023 Q3 earnings on February 9, 2024 (EST), with actual revenue of 0 USD and EPS of 0 USD

Bon Natural Life released FY2023 Q2 earnings on September 11 (EST), actual revenue USD 7.075 M, actual EPS USD 29.5091

Bon Natural Life released FY2023 Q1 earnings on September 11 (EST), actual revenue USD 7.075 M, actual EPS USD 29.5091

Bon Natural Life released FY2023 Semi-Annual earnings on September 11 (EST), actual revenue USD 14.15 M (forecast USD 17.75 M), actual EPS USD 59.0182

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Shin-Etsu Chemical Co., Ltd.

Givaudan

Symrise

Newmarket

Balchem

Sensient Tech

Flotek Industries

Ascent Ind

Solesence

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Bon Natural Life(BON.US)